Portal de Periódicos da CAPES

Human Hemoglobin Conjugated to Carboxylate Dextran as a Potential Red Blood Cell Substitute.-II-Pharmacotoxicological Evaluation

1994; Marcel Dekker; Volume: 22; Issue: 3 Linguagem: Inglês

10.3109/10731199409117882

1532-4184

Patrick Menu, B. Faivre, Pierre Labrude, Pierre Riffard, M. Grandgeorge, C. Vigneron,

Neonatal Health and Biochemistry

AbstractA solution of human hemoglobin bound to benzene tetracarboxylate substituted dextran, whose physicochemical characteristics are defined in part I, was evaluated in vivo as a potential red blood cell substitute [1]. Further experiments show:-the confirmation of a lack of acute toxicity in mice and guinea pigs after injection of 12.5%, 25% and 50% of the blood mass and the absence of death in rabbits having undergone three successive 25% hemorrhagic shocks in three week intervals.- a plasma half-life of 95 ± 0.5 hours in 70–75% hemorrhagic shocks on guinea pigs and the absence of dex-BTC-Hb in thoracic and abdominal cavities. No tissue oedema was noticed. Total hemoglobinuria did not exceed 10% of the injected hemoglobin quantity and only involved free hemoglobin.- a lack of deato in 70–75% hemorrhagic shocks and survival times ranging from 10 hours to 3 days in total exchange transfusions in guinea pig experiments.